HighHelicobacter pyloricure rate with sitafloxacin-based triple therapy

Efficacy of TailoredHelicobacter pyloriEradication Treatment Based on Clarithromycin Susceptibility and Maintenance of Acid Secretion

(2014) Mitsushige Sugimoto et al.   HELICOBACTER

Eradication of H. pylori Infection in Patients Allergic to Penicillin Using Triple Therapy with a PPI, Metronidazole and Sitafloxacin

(2014) Takahisa Furuta et al.   INTERNAL MEDICINE

Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan

(2013) Kazunari Murakami et al.   JOURNAL OF GASTROENTEROLOGY

Sitafloxacin-based third-line rescue regimens forHelicobacter pyloriinfection in Japan

(2013) Takahisa Furuta et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Eradication of Helicobacter pylori According to 23S Ribosomal RNA Point Mutations Associated With Clarithromycin Resistance

(2013) H. J. Lee et al.   JOURNAL OF INFECTIOUS DISEASES

Rabeprazole 10 mg q.d.s. decreases 24-h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype

(2012) M. Sugimoto et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Management ofHelicobacter pyloriinfection—the Maastricht IV/ Florence Consensus Report

(2012) Peter Malfertheiner et al.   GUT

Sitafloxacin resistance in Helicobacter pylori isolates and sitafloxacin-based triple therapy as a third-line regimen in Japan

(2012) Yoshihiro Hirata et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Efficacy of Sitafloxacin-Based Rescue Therapy for Helicobacter pylori after Failures of First- and Second-Line Therapies

(2011) Juntaro Matsuzaki et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Genotypic Resistance inHelicobacter pyloriStrains Correlates with Susceptibility Test and Treatment Outcomes after Levofloxacin- and Clarithromycin-Based Therapies

(2010) Jyh-Ming Liou et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Sitafloxacin and Garenoxacin May Overcome the Antibiotic Resistance of Helicobacter pylori with gyrA Mutation

(2009) H. Suzuki et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Sitafloxacin Activity against Helicobacter pylori Isolates, Including Those with gyrA Mutations

(2009) K. Murakami et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Tailored eradication therapy based on fecalHelicobacter pyloriclarithromycin sensitivities

(2008) Takashi Kawai et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

New concepts of resistance in the treatment of Helicobacter pylori infections

(2008) David Y Graham et al.   Nature clinical practice. Gastroenterology & hepatology